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Abstract: Complicated intra-abdominal and skin and skin structure infections are widely 
varied in presentation. These infections very often lead to an increase in length of hospital stay, 
with a resulting increase in costs and mortality. In addition, these infections may be caused by 
a wide variety of bacteria and are often polymicrobial with the possibility of the presence of 
antimicrobial-resistant strains, such as methicillin-resistant Staphylococcus aureus, vancomycin-
resistant enterococci, extended-spectrum β-lactamase strains (Escherichia coli, Klebsiella pneu-
moniae), and K. pneumoniae carbapenemase-producing strains. In combination with patients’ 
immunosuppression or comorbidities, the treatment and management options for initial therapy 
success are few. Tigecycline, a new glycylcyline antimicrobial from the tetracycline drug class, 
represents a viable option for the successful treatment of these infections. It has been shown to 
have activity against a wide variety of bacteria, including the antimicrobial-resistant strains. As 
with all tetracycline drugs, it is not recommended for pregnant or nursing women. The potential 
side effects are those typical of tetracycline drugs: nausea, vomiting, and headaches. Drug–drug 
interactions are not expected, and renal function monitoring is not necessary.
Keywords: complicated intra-abdominal infections, complicated skin and skin structure infec-
tions, tigecycline
Introduction
Complicated intra-abdominal infections (cIAIs) and complicated skin and skin structure 
infections (cSSSIs) are responsible for increased morbidity and mortality in affected 
patients and lead to greatly increased health care costs due to extra treatment require-
ments and extended hospitalization. Failure to initiate a proper therapy regimen early 
in the course of treatment is also responsible for the increased morbidity and mortality. 
This could include failure to initiate antimicrobial therapy, administration of an inap-
propriate antimicrobial agent, or inappropriate dosing or monitoring of antimicrobial 
therapy. These issues most commonly arise when the infectious agent is unidentified or 
when there is a delay in identification. The initial therapy may well need to be a broad-
spectrum antimicrobial, and this drug (or drugs in combination) needs to have the highest 
efficacy possible. The ever increasing threat of antimicrobial resistance from all types 
of bacteria makes the choice of an initial antimicrobial agent a major challenge.
Tigecycline, a recently developed broad-spectrum antimicrobial agent, which is 
a derivative of minocycline, was designed to be able to overcome some of the major 
antimicrobial resistance issues and has been used clinically in Europe for 4 years and in Therapeutics and Clinical Risk Management 2010:6
Table 2 Most common bacterial isolates from cSSSis
CA-cSSSIs HA-cSSSIs
Staphylococcus aureus Staphylococcus aureus
Streptococcus pyogenes Pseudomonas aeruginosa
Enterococcus species Enterococcus species
Escherichia coli
Abbreviations: cSSSIs, complicated skin and skin structure infections; CA-cSSSIs, 
community  acquired–complicated  skin  and  skin  structure  infections;  HA-cSSSIs, 
hospital acquired–complicated skin and skin structure infections.
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the Uniteds States for 3 years. It is approved for use in both 
cIAIs and cSSSIs, and it shows promise for use in community-
acquired (CA) pneumonia infections. Tigecycline has shown 
favorable antimicrobial activity against a wide range of bac-
teria including Gram-positive, Gram-negative, and anaerobic 
strains, some of these strains being those that exhibit serious 
antimicrobial resistance.1,2
In order to be able to properly manage cIAIs and cSSSIs, 
it is necessary to have an understanding of what these con-
ditions encompass. An uncomplicated IAI usually involves 
only a single organ and the infection stays localized to that 
site. These infections are usually treated using only antibi-
otic therapy or, if necessary, surgical resection. In cIAIs, 
the infections spread beyond the local site, with a resulting 
peritonitis (or abscess). Peritonitis is further categorized 
as primary (no loss of integrity of the gastrointestinal [GI] 
tract), secondary (loss of GI tract integrity, usually by per-
foration or from infected viscera such as the appendix), and 
tertiary (recurrent infection following a primary or second-
ary peritonitis).3–6 In addition, secondary cIAIs are usually 
polymicrobial, with a potential mixture of Gram-negative 
and Gram-positive aerobic and anaerobic bacteria. There 
may be so many different or varied types of bacteria present, 
including some potentially antimicrobial-resistant strains that 
all may not be able to be isolated and identified. The most 
commonly isolated nonanaerobes are the Gram-  negative 
Enterobacter species, E. coli, Klebsiella species, Proteus 
species, and Pseudomonas aeruginosa and the Gram-positive 
Enterococcus species, Staphylococcus species and Strepto-
coccus species. The most commonly isolated anaerobes are 
Bacteroides species, Clostridium species, Fusobacterium 
species, and Peptostreptococcus species. Candida species 
may also be isolated.7–11 Table 1 lists the common isolates 
from these infections.
SSSIs may be classified into four levels: (1) localized 
with no complications; (2) localized, but with comorbidity, 
or systemic and stable; (3) having toxic symptoms or no 
toxic symptoms with an unstable comorbidity; and (4) hav-
ing sepsis syndrome or with other life-threatening infection.12 
These infections are generally considered to be complicated 
if they fall into classes 2, 3, or 4.13 More generally, cSSSIs 
are described as those infections that have moved deeper 
into structures such as the fascia or muscles and/or require 
surgical intervention.14,15 Other pertinent divisions of cSS-
SIs may include CA vs hospital-acquired (HA) infections, 
chronic vs acute, localized vs diffuse, and non necrotizing vs 
necrotizing.15,16 Uncomplicated SSSIs are more likely to be 
monomicrobial, and the most common isolates from these 
infections and from   CA-cSSSIs are Gram-positive cocci 
(staphylococci,   streptococci, enterococci).12,15,17,18 Complicated 
SSSIs and HA-cSSSIs are more likely to be   polymicrobial (or 
monomicrobial if the isolate is an antimicrobial-resistant 
strain),19 with isolates including similar Gram-positive cocci 
plus varying isolates depending on the type and site of trauma 
involved. The most common additional isolates are members 
of the Enterobacteriaceae (E. coli, Enterobacter species, 
Klebsiella species, Proteus species, Serratia species) and 
P . aeruginosa.15,20,21 Table 2 lists the most common isolates 
from cSSSIs.
The types of organisms isolated and the severity of mor-
bidity and mortality in cIAIs and cSSSIs are extremely varied 
and depend on additional risk factors. These factors fall into 
two general divisions: those associated with patient’s status, 
such as comorbidities (eg, diabetes mellitus), critical illnesses 
of any kind, age (eg, infants, the elderly), immunocompetency 
(compromised: eg, human immunodeficiency virus [HIV] and 
transplant patients), liver and/or kidney disease, and vascular 
Table 1 Common isolates from intra-abdominal infections
Primary  
peritonitis
Usually  
monomicrobial
enterobacteria 
Staphylococci
Streptococci
Secondary  
peritonitis
Usually  
polymicrobial
Nonanaerobes
Enterobacter species
enterococci
Escherichia coli
Klebsiella species
Proteus species
Pseudomonas aeruginosa
Staphylococci
Streptococci
Anaerobes
Bacteroides species
Clostridium species
Fusobacterium species
Peptostreptococcus species
Candida species
Tertiary  
peritonitis
Depends on cause enterococci
Pseudomonas aeruginosa
Staphylococci
Candida speciesTherapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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sufficiency; and those associated with the type of causative 
trauma, and whether the trauma is CA or HA.21–24
Impact on morbidity, mortality,  
and costs
Studies performed on recently collected data from vari-
ous health care facilities provide useful information on 
the seriousness of the issues involved in the treatment of 
cIAIs and cSSSIs. Because patients with cIAIs and cSSSIs 
are usually hospitalized, they are at high risk of develop-
ing an additional health care-associated infection (HAI). 
A study of data from 994 acute care hospitals across the 
United States in 2000 found that the hospitalized patients 
were at risk for what were termed “medical injuries” while 
in the hospital. These injuries included events such as 
accidental puncture or laceration, complications of anes-
thesia, iatrogenic pneumothorax, postoperative hemorrhage 
or hematoma, postoperative hip fracture, postoperative 
pulmonary embolism, postoperative sepsis, postoperative 
wound dehiscence, and transfusion reaction. Patients who 
developed postoperative sepsis averaged over 10 days 
each of excess hospitalization, resulting in an average of 
almost US$58,000 each in extra health care costs and an 
average of almost 22% increase in mortality. Patients who 
experienced wound dehiscence averaged almost 10 extra 
days of hospitalization, over US$40,000 in extra costs, and 
an increase in mortality rate of almost 10%.25 A study on 
data from 283 hospitals in the United States in 2002 that 
analyzed HAIs categorized into five major types (surgical 
site, bloodstream, pneumonia, urinary tract infections, 
and other combined infections) found that an estimated 
1.7 million HAIs resulted in nearly 99,000 deaths for that 
year.26 This number exceeded the number of deaths from 
any notifiable disease.27
Two other studies collected data on patients with IAI. The 
first study analyzed data from the Netherlands and found that 
hospitalized patients with complicated (secondary) IAIs who 
had not been given appropriate initial antibiotic treatment 
(16%) had over a three fold higher risk of clinical failure 
than those given appropriate treatment. This resulted in an 
average increased hospital stay of over 7 days and an average 
excess in costs of over �6,000.28 The other study analyzed 
data from the year 2000 in the United States on patients who 
underwent intra-abdominal surgery and developed postop-
erative pneumonia. The data from 994 hospitals in 28 states 
showed that of the more than 600,000 patients that had intra-
abdominal surgery, over 13,000 developed pneumonia and 
almost 11% of them died. Developing pneumonia resulted 
in an average of over 11 days of extra hospitalization and 
over US $31,000 in average excess costs, which was a mean 
increase in costs of 75%.29
A study on hospitalized patients with cSSSIs analyzed 
data from over 400 US hospitals during 2003–2004. The 
study included over 47,000 patients, almost 11,000 (nearly 
23%) of which experienced a failure of initial antibiotic 
therapy. This resulted in an average of over 5 days of extra 
hospitalization, an average of over US $5,000 in excess costs, 
and a three fold increase in mortality.30
Increasing problem of antimicrobial 
resistance
An extremely important issue that adds to the complexity 
of management and treatment of cIAIs and cSSSIs is the 
ever-increasing problem of antimicrobial-resistant bacteria. 
Several of the most common isolates from these types of 
infections are bacteria that are at the forefront in the antimi-
crobial-resistance issue. These include methicillin-resistant 
S. aureus (MRSA), vancomycin-resistant enterococci (VRE), 
extended-spectrum β-lactamase (ESBL)-producing bacteria 
(E. coli and K pneumonia), K. pneumoniae carbapenemase 
(KPC)-producing bacteria (K. pneumonia, Enterobacter 
species, E. coli, and Pseudomonas species), P . aeruginosa 
(which has other antimicrobial capabilities), and anaerobic 
bacteria having various antimicrobial mechanisms (Bacte-
roides species and Clostridium species). Table 3 represents a 
list of antimicrobial agents that are not effective against these 
resistant organisms.
Methicillin-resistant S. aureus
The most common isolate from cSSSIs and a frequent isolate 
from cIAIs is S. aureus. This means that any antimicrobial 
mechanism in these bacteria could be a major management 
and treatment issue. The percentage of isolates of S. aureus 
that are methicillin-resistant strains has been increasing 
steadily since first discovered, with a current average in the 
United States of nearly 60%.31 In addition, there is the issue 
of CA-MRSA strains vs HA-MRSA strains. Although the 
CA-MRSA usually are not resistant to other drug classes, the 
HA-MRSA have been found to be resistant to multiple drug 
classes, such as the aminoglycosides and fluoroquinolones, 
and a few isolates have recently been found to be resistant to 
vancomycin.32 The CA-MRSA, however, are most likely to 
produce the Panton–Valentine leukocidin, which is associ-
ated with cSSSIs that are highly virulent and with cases of 
necrotizing fasciitis.33 An important variation in resistance 
among the CA-MRSA strains involves the main European Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Table 3 Antimicrobial agents that are not effective against resistant 
organisms
MRSA
CA β-lactam drugs
HA β-lactam drugs
Aminoglycosides
Fluoroquinolones
Oxazolidinones
Streptogamins
Tetracycline
Trimethoprim-sulfamethoxazole
vancomycin – beginning
vRe vancomycin
  associated with ampicillin resistance
Aminoglycosides
Clindamycin
erythromycin
Tetracycline
Trimethoprim-sulfamethoxazole
  facilitate colonization
Aminoglycosides
Extended-spectrum cephalosporins
Fluoroquinolones
eSBLs Aminoglycosides
β-lactam drugs, including third-generation cephalosporins, 
monobactams, and sometimes carbapenems (KPCs)
Sulfonamides
Anaerobes β-lactam drugs – most increasing resistance to 
cephalosporins
Chloramphenicol – some strains
Clindamycin – low to moderate resistance
Metronidazole – in the Gram-positives
Quinolones – low to moderate resistance
Tetracycline – most B. fragilis strains, also found in C. 
perfringens
Abbreviations: MRSA, methicillin-resistant S. aureus; CA, community-acquired; 
HA, hospital-acquired; VRE, vancomycin-resistant enterococci; ESBLs, extended-
spectrum β-lactamases; KPCs, K. pneumoniae carbapenemases.
CA-MRSA strain, the ST80 strain. It has been isolated 
in several countries including Belgium, England, France, 
  Germany, Switzerland, and the Netherlands. Isolates from 
areas that include Europe, Greece, and China have been 
shown to be highly resistant to tetracycline. The usual mecha-
nism of resistance in these strains is via the tetK gene, which 
encodes an efflux pump.34–36 Although the tetK gene confers 
tetracycline resistance, these isolates are usually susceptible 
to minocycline.37 These resistance issues severely limit the 
possibilities for antimicrobial therapy. Infections with MRSA 
also increase health care costs, length of hospital stay, and 
mortality in already complicated infections.38 It has been 
estimated that each year over 126,000 people are hospitalized 
with MRSA infections. These infections result in an average 
excess cost of US $20,000 per case.39 An extremely disturbing 
fact is that now more deaths per year in the United States 
are attributed to MRSA than those from tuberculosis and 
HIV/AIDS combined.40,41
Vancomycin-resistant enterococci
Enterococci are frequent isolates from cSSSIs and cIAIs. 
Approximately 95% of these isolates are Enterococcus 
faecalis and E. faecium strains.42 The majority of VRE strains 
are E. faecium, which are also highly resistant to ampicillin. 
VRE are believed to be natural colonizers in the GI tract, and 
infections are most often seen in patients who are immuno-
compromised and who have received antimicrobial therapy 
with multiple drugs.43,44 Enterococci have been found to 
be resistant to many types of antimicrobial agents, such as 
clindamycin, trimethoprim-sulfamethoxazole, aminoglyco-
sides, and tetracyclines. In addition, it has been found that 
certain antimicrobials (extended-spectrum cephalosporins, 
fluoroquinolones) actually facilitate colonization of VRE, 
so the possibilities for antimicrobial therapy are extremely 
restricted.42–44 Clinical isolates of VRE are continuing to 
increase in numbers, with rates in the United States in the 
20%–40% range. In Europe, the numbers are also increas-
ing, but the overall rate is lower (around 10%). It has been 
postulated that the higher resistance rates in the United States 
correlate with a higher use rate of vancomycin therapy.45,46 
VRE infections also have a very serious impact on health 
care, with an average increase in hospital stay of over 6 days, 
an average increase in cost of almost US $13,000 per infec-
tion, and an average increased mortality of 6%.47
Extended-spectrum β-lactamases
Enzymes that work against the β-lactam drugs (penicillins, 
cephalosporins, monobactams, carbapenems) are known 
collectively as β-lactamases. The enzymes can be classi-
fied functionally into groups (the Bush–Jacoby–Medeiros 
classification scheme groups 1–4) and/or by the molecular 
makeup of their nucleotide and amino acid sequences (the 
Ambler groups A–D).48 Over 200 ESBLs, which occur in 
Gram-negative bacteria, are known, most of which are clas-
sified functionally into group 2be and into Ambler group 
A. The enzymes in this group inactivate third-generation 
cephalosporins and monobactams but are usually inhibited 
by the β-lactamase inhibitor, clavulanic acid.49 The genes 
for ESBLs are usually located on plasmids, and these same 
plasmids often carry genes for aminoglycoside and sulfon-
amide resistance as well.50 ESBLs are found most often in the 
Enterobacteriaceae, particularly in E. coli and K pneumoniae, 
and also in P . aeruginosa.49,51 These same organisms may 
also carry genes for producing other β-lactamases such Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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as the AmpC-type enzymes and carbapenemases (such as 
the KPCs), which may not be inactivated by β-lactamase 
inhibitors.48,49,51 The ESBL-carrying organisms are among the 
most clinically important isolates from cIAIs and HA-cSSSIs. 
The most serious issue when dealing with these organisms 
is the consequence of inappropriate use of antimicrobial 
agents during initial therapy. Because the β-lactam drugs 
have activity against the structure of the peptidoglycan layer 
in the bacterial cell wall and Gram-negative bacteria (unlike 
Gram-positive bacteria) have a thin peptidoglycan layer that 
is somewhat protected by the much thicker outer lipopoly-
saccharide layer, it is probably best in complicated diseases 
to use antimicrobial agents from one or more of the other 
drug classes instead. The use of monotherapy or combination 
therapy with various β-lactam drugs has shown to result in 
treatment failure in many patients, with an accompanying 
increase in mortality.52–55 In addition, infections with ESBL 
organisms increase the length of hospital stay with a resulting 
increase in costs.52,56
Anaerobes
Anaerobic bacteria are sometimes significant isolates from 
cIAIs. Due to the production of β-lactamases, most anaerobic 
bacteria are highly resistant to the penicillin drugs, with low 
to moderate, but increasing resistance to the cephalosporins 
and emerging resistance to the carbapenems. Most anaerobes 
are also resistant to the aminoglycosides. Clindamycin resis-
tance is low to moderate and increasing, especially among 
Bacteroides fragilis strains.57–61 B. fragilis, which is the most 
common anaerobic clinical isolate, is also highly resistant 
to tetracycline (up to 90% of strains), has shown moderate 
resistance to quinolones and fluoroquinolones, and varied 
low-level resistance to chloramphenicol and metronidazole. 
Clostridium species have shown a high level of resistance 
to clindamycin (67%), and some tetracycline isolates have 
been isolated.57,59
Management issues in patients  
with comorbidities
There are a number of variables that come into play during 
the management of complicated infections that affect patient’s 
outcome. These potential additional factors can be directly 
responsible for increased length of hospital stay, increased 
costs, and increased mortality. Some of these factors are 
influenced by the variables in the complicated infections 
themselves, and some factors, such as preexisting comor-
bidities, necessitate changes in management and treatment. 
In addition to the general factor of the site of any initiating 
trauma, cSSSIs are also influenced by major   factors such as 
an initial infection with MRSA or whether the major trauma 
was burn related; and cIAIs are influenced by additional 
major factors such as organ repair, removal, and/or transplant. 
Whenever immune system depression is involved, whether as 
a result of an infection or condition, or because immunosup-
pressing drugs are part of the therapy, the risk of complicated 
infection and mortality is much higher. It is interesting to note 
that patients with cIAIs that occur as a result of complicated 
appendicitis have a lower mortality rate than those with cIAIs 
from other causes, and patients who acquire an IAI in the 
hospital (nosocomial IAIs) have a higher mortality rate than 
those acquired in the community.62
If the initial infection in a cSSSI is caused by MRSA, 
then the management issues depend on whether the MRSA 
strain is a CA-MRSA or an HA-MRSA. CA-MRSA tend 
to be resistant only to β-lactam drugs, whereas HA-MRSA 
often are resistant to multiple drug classes. In addition, the 
CA-MRSA strains usually carry an additional virulence 
factor, the Panton–Valentine leukocidin, which can lead to 
a necrotizing infection. Management of these MRSA infec-
tions requires appropriate initial antimicrobial therapy, which 
in turn requires expedited identification and susceptibility 
data. Failure to implement the proper antimicrobial therapy 
early in these infections can lead to a significant increase in 
mortality. MRSA infections are also a major cause of cSSSIs 
and cIAIs when the initial trauma was from a skin injury or 
from surgery.
There are an estimated two million serious burn injuries 
per year in the United States.63 If the patient is a burn victim, 
especially with third-degree burns, he or she is at high risk 
for development of infection in the burn wounds. Because 
severely burned individuals are usually admitted to a health 
care facility immediately, they are at high risk for nosocomial 
infections. The complications in burn wounds that are major 
issues include the amount of loss of skin area and whether 
there is also inhalation damage.64,65 Severe damage to the 
epithelial layers of the skin triggers an immune response 
that leads to immune system dysfunction, which results in a 
much higher risk for infection.63,66 These complications and 
infections can result in the spread of infection into the blood 
stream and can lead to organ system failure.63–65 The most 
common isolate from burn infections is P . aeruginosa. Fol-
lowing in close second place as an isolate is Acinetobacter 
baumannii. Both of these organisms are usually found to 
be resistant to multiple classes of antimicrobial agents.65,67 
These complications can result is severely limited treatment 
options for patients with burn injuries.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Patients with comorbidities
Patients with special comorbidities, such as HIV infection or 
cancer, have special treatment issues. Because of a potential 
crippling of the immune system, HIV patients are at high risk 
for developing many types of opportunistic infections with 
fungi, parasites, viruses, and bacteria. The most common bac-
terial infections are caused by Mycobacterium species. HIV 
patients are given prophylactic treatment for opportunistic 
infections based on their response to antiretroviral treatment. 
An increase in CD4+ lymphocyte number to certain specified 
levels may indicate that prophylactic treatment is no longer 
needed. Studies have shown that when HIV patients have 
acceptable lymphocyte levels, they are at low risk for develop-
ing opportunistic infections.68–70 If an HIV patient develops 
a cSSSI or cIAI, then the treatment will depend on his or 
her immune status and the particular bacteria involved. HIV 
patients are also at high risk of developing certain types of 
cancers. Another therapy issue occurs with the antiretroviral 
drug didanosine. Because it interferes with the absorption of 
fluoroquinolones and tetracyclines, the patient needs to be 
instructed to stagger the two drug types with 2 hours between 
the alternate doses.71,72
The presence of cancer as a comorbidity can have a mul-
titude of effects on patients with cSSSIs and cIAIs. As with 
HIV , patients with cancer that require chemotherapy are at 
risk for development of some of the same types of opportu-
nistic infections. The most common opportunistic bacterial 
isolates are Gram-positive streptococci and staphylococci.73,74 
Prophylactic treatment is not usually recommended, and 
antimicrobial choices are based not only on the causative 
organism but also on the level of neutropenia and the pres-
ence of a fever or other symptoms of an infection.74,75 Because 
cancer can be a localized or systemic disease, the treatment 
and management of patients with cSSSIs and cIAIs will need 
to be tailored for the needs of the individual patient. There 
is a lack of information on antimicrobial drug interactions 
in cancer patients. However, the Infectious Diseases Society 
of America recommends in its guidelines for antimicrobial 
therapy in cancer patients that to avoid the possibility of 
renal toxicity, cisplatin, amphotericin B, cyclosporine, 
vancomycin, and the aminoglycosides should not be used 
in combination.75
There are many general concerns in transplant patients 
because they are put on immunosuppressive therapy, so they 
are at high risk of developing infections. They have to be 
monitored carefully for any symptoms. Each type of infec-
tion has to be dealt with on an individual basis. There are 
some therapy concerns when using cyclosporine (and related 
drugs). Cyclosporine has an additive nephrotoxicity when 
used with aminoglycosides, it can lower the drug metabolism 
of erythromycin, and can increase the drug metabolism of 
rifampin.72
Patients with diabetes
Patients with diabetes have a high risk of developing infec-
tions in their lower extremities. Excess glucose present in 
the blood stream can result in impaired microvascular cir-
culation and peripheral motor neuropathy, which may lead 
to an increased infection risk. Any skin-damaging injury or 
surgery is a huge infection risk factor. In addition, because of 
the circulation and neuropathy issues, infected tissues do not 
heal as easily as in nondiabetic patients. An estimated 25% 
of adult diabetics (the risk increases with age) will develop a 
foot infection, and this infection will lead to amputations and 
increased mortality.76–78 The usual bacterial isolate from mild 
to moderate foot infections are Gram-positive cocci, with an 
accompanying risk of MRSA infection. More severe infec-
tions may be polymicrobial and also may include members of 
the Enterobacteriaceae and anaerobes.76,79 Even without any 
additional health issues such as surgery, diabetic patients have 
a good chance of having to undergo antimicrobial therapy. 
There can be some issues related to antimicrobial drugs and 
the medications that the diabetic patient takes to lower his or 
her glucose levels competing with each other in metabolic 
pathways. This can lead to hypoglycemia or hyperglycemia, 
so a diabetic patient should be monitored carefully while on 
antimicrobial therapy.80–82
Patients with renal or hepatic failure
Patients with impaired renal function are not only at risk 
for development of an infection but also the loss of renal 
function can also directly affect the efficiency of any 
antimicrobial therapy. The extent of the effect depends on 
the amount of lost function and the type of antimicrobial 
agent used. Antimicrobial compounds that are hydrophilic 
are generally excreted through the kidney. Those that are 
lipophilic may be metabolized first (often by the liver) and 
then eliminated.83,84 In addition, patients who undergo some 
type of dialysis will likely lose some of any antimicrobial 
drug during that process. These patients need to be carefully 
monitored, if possible, for drug levels.85–87 Patients who do 
not maintain optimal drug levels will then have increased 
length of hospital stay and a higher risk of mortality.88 
Patients who have to undergo kidney transplantation are 
also at high risk of infection because of the necessary 
immunosuppression therapy.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Impaired liver function can lead to a multitude of 
  problems. Patients with acute liver failure (ALF) are at high 
risk of infection, and this will commonly lead to multiple sys-
tem organ failure, which is the most common cause of death 
in these patients.89 Approximately 50% of ALF patients will 
undergo liver transplantation. Immunosuppressive therapy 
after transplantation puts them at high risk of infection, and 
bacterial and fungal infections are responsible for nearly 
one-third of deaths that occur after transplantation. For this 
reason, patients who are to undergo a liver transplant are 
usually given extensive prophylactic therapy.90 Cirrhosis of 
the liver, which is most often caused by hepatitis C infec-
tion or alcoholic liver disease, is responsible for up to 80% 
of adult liver transplants.91 Because the liver is responsible 
for metabolizing many clinically important drugs (including 
lipophilic antimicrobial agents), when there is decreased 
function, the metabolism of these drugs can be greatly 
reduced, and patients have to be carefully monitored because 
of this.83,92
Antibiotic selection
There are certain considerations that need to be addressed 
before determining any initial, or in the case of previously 
failed therapy, additional antimicrobial therapy for any 
type of infection. The first consideration for deciding on 
antimicrobial therapy should be CA or HA. Even with 
the same organism (eg, MRSA), the susceptibilities can 
vary greatly between these two parameters. Other factors 
to take into consideration include chronic or acute infec-
tion, patient’s history of similar infections, patient’s history 
of antimicrobial use (including any known antimicrobial 
allergies), and treatment history for the current infection. 
With these facts in hand, the physician can be on the watch 
for potential antimicrobial-resistant organisms. Then, the 
patient’s health status needs to be considered. Is the patient 
immunosuppressed, does he or she have diabetes or other 
comorbidities, or is he or she on chemotherapy? Then, with 
a careful examination of the patient and proper sampling of 
the infection site, a Gram stain report (and later a culture 
report, if ordered) can provide the physician with important 
information about the infection: is there only one organism 
present (predominately) or is it a polymicrobial infection; 
are bacteria only present and/or fungi; Gram-positive and/or 
Gram-negative? In addition, the physician has to assess the 
infection for signs that suggest an anaerobic bacterial infec-
tion. Now, the physician can make an informed decision on 
the choice of antimicrobial therapy, which may necessitate 
initial use of a broad-spectrum drug (or drug combination 
if the infection is polymicrobial), then changing to a more 
specific drug when information on organisms’ identification 
and drug susceptibility is available.
Complicated skin and skin structure 
infections
Although most cSSSIs are caused by Gram-positive 
cocci, there is a difference in the organisms isolated from 
CA-cSSSIs and HA-cSSSIs, such as MRSA. In addition, 
some of the Gram-negative bacteria are common isolates 
from HA-cSSSIs. It is best to use this parameter as a guide 
for initial antimicrobial therapy options, especially if a Gram 
stain report is not available or is delayed. Infection with 
Streptococcus species usually respond favorable to standard 
semisynthetic penicillin or early generation cephalosporins. 
However, if the patient is allergic to penicillin and because the 
group A streptococci are showing resistance to erythromycin, 
a lincosamide such as clindamycin could be used. Because 
of increasing resistance to these drugs, it might be best to 
use drugs from antimicrobial classes that have different foci 
(eg, cell-wall inhibition, protein synthesis inhibition) in 
combination.19,93
The other causative organisms mentioned in Table 2 are 
among the serious antimicrobial resistance organisms, and 
therefore have to be treated with extreme care. When deciding 
on initial antimicrobial therapy, before definitive organism 
antimicrobial susceptibility data are available, it might be 
prudent to err on the side of caution. Basing the initial therapy 
on the assumption that the causative organism might be a 
resistant one may be the safer option. When susceptibility 
data become available, the antimicrobial therapy can then 
be tailored for the specific organism. If the physician waits 
to treat resistant organisms until they have been identified, 
the infection may then be out of control and mortality rates 
will increase greatly.
Because the incidence of MRSA among S. aureus isolates 
is so high (nearly two of every three isolates in the United 
States), it may be best to treat all isolates as if they were 
MRSA. Antimicrobial therapy can be based on CA (not usu-
ally multidrug resistant) vs HA (often multidrug resistant) 
guidelines. Most CA-MRSA strains are susceptible to tetracy-
clines, fluoroquinolones, trimethoprim or sulfamethoxazole, 
clindamycin, and vancomycin. Vancomycin is probably not 
needed for CA-MRSA infections and perhaps should not 
be used as initial therapy. Clindamycin therapy has issues 
because resistance can be induced in some MRSA strains. 
For serious HA-MRSA infections, vancomycin is the current 
accepted standard treatment.19,93,94Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
426
Reygaert
Serious infections with VRE are a major treatment issue. 
The percentage of Enterococcus species isolates that are 
vancomycin resistant is increasing at an alarming rate. Recent 
antimicrobial susceptibility studies recommend the use of the 
newer glycopeptide or glycylcyline drugs.95,96
Gram-negative bacteria isolated from HA-cSSSIs may 
be strains that are ESBLs or possibly P . aeruginosa, which 
is naturally resistant to multiple drugs. The potential ESBL 
organisms, E. coli and K. pneumoniae, may also be resistant 
to multiple drugs. The suggested antimicrobial therapy for 
ESBL organisms is to use carbapenem, fluoroquinolone, or 
aminoglycoside drugs, alone or in combination.48,49 In addi-
tion, some K. pneumoniae isolates may produce carbapen-
emases (KPCs), so carbapenem drugs would not be an option 
for such isolates. Potential antimicrobials that can be used 
for P . aeruginosa infection include piperacillin or ticarcillin, 
some third-generation and fourth-generation cephalosporins, 
aztreonam, active carbapenems, ciprofloxacin or levofloxa-
cin, and certain aminoglycosides (gentamicin, tobramycin, 
amikacin).23,97
Anaerobes may sometimes be isolated from serious dia-
betic foot infections. The most commonly isolated anaerobe 
is Clostridium perfringens, which is a rapid grower and a 
potential cause of necrotizing and “gas gangrene” infections. 
Because it grows so rapidly, it is important to initiate anti-
microbial therapy quickly. Recommended therapy includes 
penicillin G and clindamycin in combination. Patients who 
are allergic to penicillin are usually given clindamycin or 
metronidazole.98
Complicated intra-abdominal infections
Many of the same organisms that cause cSSSIs are also 
isolated from cIAIs with similar antimicrobial therapy 
recommendations. Gram-positive cocci (Streptococcus 
species, MRSA, VRE) may have the same antimicrobial 
resistance issues. Some of the most common Gram-negative 
isolates are potential ESBL strains or P . aeruginosa, with 
similar antimicrobial therapy recommendations. Potential 
anaerobic isolates include Clostridium species, with simi-
lar recommended therapy, and Bacteroides species, which 
may have resistance to multiple drugs. The current recom-
mended antimicrobial therapy for Bacteroides species is 
metronidazole or chloramphenicol.59,60 In addition to all 
the potential antimicrobial-resistant strains, cIAIs are most 
often polymicrobial infections, not only with Gram-positive 
and Gram-negative but also with nonanaerobes, anaerobes, 
and potentially with yeast such as Candida species or other 
fungi. This means that some sort of complicated combination 
therapy will probably be needed. The risk of improper initial 
antimicrobial therapy failing is very high in these infections 
and leads to greatly increased mortality rates.9
Clinical utility of tigecycline
Tigecycline is currently approved for intravenous use in 
cSSSIs and cIAIs. It is a glycylcyline drug semisynthetically 
derived from the tetracycline drug, minocycline, by addition 
of a 9-t-butylglycylamido group. It binds reversibly to the 
30S bacterial ribosomal subunit and blocks the tRNAs from 
being able to enter the ribosome A site, effectively inhibiting 
protein synthesis.99–102 The glycylamido side chain allows 
tigecycline to overcome the usual resistance mechanisms 
against the tetracycline drugs (which are produced by 
acquisition of the various tet resistance genes), resulting in a 
stronger binding affinity than that of minocycline (three fold) 
and tetracycline (20-fold), allowing it to bind well to TetM-
modified ribosomes, and keeping tigecycline from being 
transported out of the bacteria via a tetracycline-specific 
efflux pump.99,103,104 Given intravenously in a usual dosing 
regimen of 100 mg initially and then 50 mg every 12 hours, 
tigecycline exhibits a large volume of distribution (7–9 L/kg) 
with good tissue penetration. Concentrations of tigecycline 
in various tissues compared with serum concentrations are 
typically 38-fold in the gallbladder, 8–9-fold in the lung, 
and over two fold in the colon, with a steady state plasma 
concentration of 0.87 µg/mL and a mean terminal half-life of 
37–38 hours.105 It has a rapid uptake into polymorphonuclear 
neutrophils, which peaks at approximately 1 hour after dosing 
and is 20–30-fold higher than the extracellular concentra-
tion.105,106 Tigecycline is not metabolized in the liver and 
is independent of the CYP450 system, so it does not affect 
drugs that are metabolized by these enzymes, which means 
that there is no required monitoring of renal function, and 
there is a low potential for drug–drug interactions.99,105,107,108 
It is excreted predominately unchanged, with about 59% 
excreted in feces and 22%–32% excreted in urine.104 The only 
adverse effects were those similar to the tetracycline drugs: 
nausea, vomiting, and headache.99,107 Costs must be taken into 
consideration when choosing antimicrobial therapy, but when 
faced with potentially life-threatening infections, cheapest is 
not always best. The typical daily cost for tigecycline therapy 
is more than piperacillin or tazobactam but less than linezolid, 
daptomycin, or meropenem.108
Susceptibility tests have shown tigecycline to have a 
very broad spectrum of activity against bacteria, including 
the most serious threats for drug resistance in cSSSIs and 
cIAIs. These include Gram-positive cocci – MRSA, VRE; Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Gram-negativecocci– ESBLs, KPCs; and anaerobes. These 
data suggest that tigecycline could be used as monotherapy, 
or in drug combinations, for initial antimicrobial therapy, with 
an excellent chance that this therapy would be successful. 
This could lead to greatly improved infection management, 
lower costs, and decreased mortality. There were a few bac-
teria that exhibited a reduced susceptibility, and tigecycline 
monotherapy is probably not recommended for them. Those 
organisms include Proteus mirabilis, the indole-positive Pro-
teeae (Proteus vulgaris, Morganella morganii, Providentia 
species), and P . aeruginosa when isolated from the lungs of 
cystic fibrosis patients.100,101,109 It is also not recommended 
to use for pregnant or nursing women as the tetracycline 
drugs can cross the placenta and may be present in high 
concentrations in breast milk.99 Table 4 lists the bacteria that 
are susceptible to tigecycline.
Conclusion
cIAIs and cSSSIs can be very challenging to manage and treat. 
These infections vary greatly in severity based not only on 
general patients’ health (immunosuppression, comorbidities, 
etc) but also on the wide variety of bacteria that can be involved 
(Gram-positive, Gram-negative, anaerobes). These infections 
are often polymicrobial and may contain any of the most feared 
antimicrobial-resistant strains of bacteria (MRSA, VRE, ESBLs, 
KPCs). Identifying a proper antimicrobial treatment regimen for 
initial therapy is vital because failure of initial treatment cor-
relates with greatly increased costs and higher mortality rates.
The new glycylcyline antimicrobial, tigecycline, is a broad-
spectrum antibiotic and has shown activity against a wide 
variety of bacteria (including antimicrobial-resistant strains). 
Tigecycline shows great promise for use in cSSSIs and cIAIs 
especially when a broad-spectrum drug is needed for initial 
antimicrobial therapy. Even though it is only approved for 
intravenous use, this results in greater tissue penetration, which 
is highly important in these types of infections. Side effects 
may present, but are not more serious than any of the tetracy-
cline drugs. The daily cost for this drug is moderately high, 
but that cost can easily be offset when initial treatment success 
translates to shorter hospital stays and decreased mortality. 
Tigecycline seems likely to be able to fill a gap in antimicrobial 
therapy that has been widening, and perhaps will help ease the 
anxiety of physicians who face the treatment and management 
of patients with antimicrobial-resistant infections.
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